Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

NXTC

NextCure (NXTC)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NXTC
DataOraFonteTitoloSimboloCompagnia
06/03/202522:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
14/02/202519:40Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
06/02/202522:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
04/02/202500:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
03/02/202522:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
10/01/202514:05GlobeNewswire Inc.NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersNASDAQ:NXTCNextCure Inc
10/12/202414:05GlobeNewswire Inc.NextCure Announces Acceptance of IND Application for LNCB74NASDAQ:NXTCNextCure Inc
26/11/202413:00GlobeNewswire Inc.NextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
19/11/202414:05GlobeNewswire Inc.Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNASDAQ:NXTCNextCure Inc
15/11/202400:59Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
07/11/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
07/11/202422:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
05/11/202422:05GlobeNewswire Inc.NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
04/10/202415:05GlobeNewswire Inc.NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
16/09/202414:05GlobeNewswire Inc.NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024NASDAQ:NXTCNextCure Inc
01/08/202422:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
20/06/202422:10GlobeNewswire Inc.NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:NXTCNextCure Inc
30/05/202422:05GlobeNewswire Inc.NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024NASDAQ:NXTCNextCure Inc
02/05/202422:05GlobeNewswire Inc.NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
24/04/202422:05GlobeNewswire Inc.NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024NASDAQ:NXTCNextCure Inc
08/04/202413:00GlobeNewswire Inc.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024NASDAQ:NXTCNextCure Inc
04/04/202413:05GlobeNewswire Inc.NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardNASDAQ:NXTCNextCure Inc
02/04/202413:00GlobeNewswire Inc.NextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:NXTCNextCure Inc
21/03/202413:55GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
05/03/202414:05GlobeNewswire Inc.NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesNASDAQ:NXTCNextCure Inc
18/01/202422:05GlobeNewswire Inc.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersNASDAQ:NXTCNextCure Inc
21/12/202313:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryNASDAQ:NXTCNextCure Inc
14/12/202312:45GlobeNewswire Inc.NextCure Provides Year-End Clinical Pipeline UpdatesNASDAQ:NXTCNextCure Inc
20/11/202313:00GlobeNewswire Inc.NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
15/11/202322:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNASDAQ:NXTCNextCure Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NXTC
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network